SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Boston, MA, USA - July 1, 2022: The main entrance to the Vertex headquarters building in Boston, Massachusetts. Vertex Pharmaceuticals is an American biotechnology company.
Approvals
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.
December 23, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Eli Lilly's biotechnology center in California
GLP-1
Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.
December 23, 2024
 · 
2 min read
 · 
Kate Goodwin
Art collage, hands and falling coins in orange circle. Modern design of finance and business.
Venture Capitalists
To Attract VC Dollars in 2025, Biopharma Must Bring the Data: Pitchbook
High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk, Pitchbook said in its 2025 outlook.
December 23, 2024
 · 
2 min read
 · 
Annalee Armstrong
Doubtful businessman stands in front of a crossroad with road split in three different ways as arrows shows opposed courses. Business challenge, choosing a correct pathway. Difficult decision concept
Executive Appointments
After Month of Bad News, Applied Shuffles Leadership, Lays Out Uncertain Path for Rare Disease Drug
Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct during a clinical trial, the biotech’s CEO has stepped aside.
December 23, 2024
 · 
2 min read
 · 
Annalee Armstrong
Silhouette of a business person on the top of a mountain peak in sunset background. Winner and conquer of businessman concept.
Regulatory
5 Companies That Celebrated First Approvals in 2024
Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.
December 23, 2024
 · 
6 min read
 · 
Heather McKenzie
Roller coaster on sunset sky.
Neuroscience
2024 Highlights the Rollercoaster That Is Neuro
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.
December 23, 2024
 · 
6 min read
 · 
Heather McKenzie
Multi-directional arrows on yellow background , choose between several potential future options and scenarios,3d rendering
GLP-1
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists also show potential in several other indications, including cancer, addiction and neurodegenerative diseases.
December 23, 2024
 · 
11 min read
 · 
Tristan Manalac
Young businessman jumping through gap cliff at sunrise time with modern city background
GLP-1
Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.
December 20, 2024
 · 
3 min read
 · 
Annalee Armstrong
Recession arrow, Graph showing business decline on led screen
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
 · 
1 min read
 · 
Kate Goodwin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS